Instructions for Authors

General Information

Description

Clinical Oncology and Cancer Research (COCR ISSN 1674-5361, CN 12-1404/R), published quarterly in English, hosted by the Chinese Anti-Cancer Association (CACA) and Tianjin Medical University Cancer Institute and Hospital. COCR was established in 2004 and indexed in EMBASE and BIOSIS.

COCR strives to publish the highest quality manuscripts dedicated to original laboratory and clinical investigations related to oncology. COCR welcomes editorials, original research, review articles, case reports and other articles that relate to the care of patients with cancer.

Peer-review policy

COCR employs a single-blind review process, so authors do not know the identity of the reviewers. Only manuscripts of high relevance and suitability will enter into the peer review process, which will be conducted by at least two internationally known experts in the field, and will aim to ensure that all published manuscripts provide new scientific knowledge. Authors may suggest that specific individuals be or not be involved as reviewers, but the final decision of acceptance or rejection rests with the editorial board.

Randomized controlled trials

COCR recommends that authors adopt the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at external link www.icmje.org.

Ethics

Work on human beings that is submitted to COCR should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical
research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines. Patients’ and volunteers’ names, initials, and hospital numbers should not be used.

**Conflict of interest**

At the end of the text, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

**Manuscript Preparation**

Manuscripts should be typed using double spacing on A4 (297 mm×210 mm) white paper with outer margins of 2.5 cm. The manuscript should be arranged in the following order: (1) Title page, (2) Abstract, (3) Keywords, (4) Introduction, (5) Materials and Methods, (6) Results, (7) Discussion, (8) Acknowledgments, (9) References, (10) Tables, (11) Figures. All pages should be numbered.

**Title page**

The title page should contain, on separate lines, the manuscript title, all author(s) name(s), affiliations, the name, telephone and fax number and E-mail address of the corresponding author. Disclosure of any financial support for the research should be included. The title must be informative, specific, and concise, and abbreviations avoided. List the author(s) name(s) as follows: initial and/or first name, middle name or initial(s) and full family name. For example: Xishan Hao, Feng Ou-Yang, John F.Doe.

**Abstract**

Include an abstract of up to 250 words as follows: **OBJECTIVE, METHODS, RESULTS,** and **CONCLUSION.** The abstract must be informative, providing information as to why and how
the research was conducted so the reader can understand the results. Emphasize the new and important aspects of the study.

Keywords
Provide 3-10 key words or phrases that will assist readers and indexers in cross-indexing the study. Use terms recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/meshhome.html. If a suitable MeSH term is not available, a more general term for indexing may be used.

Introduction
The Introduction summarizes the rationale for the study and gives a concise background. Use references to provide the most salient background rather than an exhaustive review. The last sentence should concisely state your purpose for carrying out the study (do not include methods, results, or conclusion).

Materials and Methods
The Materials and Methods provide technical information about the study. Do not describe methodological details that have been published previously. Use the “passive voice” when describing experimental detail. Specifications (including the manufacturer, city, and the country) should be given for the main drugs, chemicals, and instruments.

Results
Emphasize or summarize only important observations. Uncomplicated data may be set forth in the text with no need for tables or figures. Give absolute values, not merely percentages, particularly for the control values. Present numerical data using only significant figures and your results followed by (Table 1 or Fig.1). Reserve extensive interpretations of the results for the Discussion section.

Discussion
Focus the discussion on your results. Do not redescribe the results, or review the current literature, or refer to textbook knowledge. Only cite references that have a close relationship with the present results. End with a brief conclusion, which should be linked with the goal stated in the Introduction. Do not include the obvious statement that further work is necessary or planned. In your conclusion avoid indefinite or ambiguous wording, such as "possible," "perhaps," "maybe," "probably," and "likely."
Acknowledgments

It is suitable to list all contributors who do not meet the criteria for authorship, such as a person who provided purely technical help, writing assistance, or a department head who provided only general support. Financial and material support should also be acknowledged, but typed on the title page after the corresponding author.

References

The Journal advocates the citation of new papers; old references are better replaced with updated ones. The authors are responsible for the correctness of references. References should be numbered consecutively in the order in which they appear in the text. Citations should be labeled with square superscript brackets and should appear in front of the period or comma at the end of the sentence/clause. Avoid using abstracts as references. "Unpublished data", and "personal communications" can not be used as references. Inappropriate references include those that are linked with a hyphen and the difference between the two numbers at two sides of the hyphen is more than 5. For example, [1-6], [2-14] and [1,3,4-10,22] are all considered as inappropriate references. The titles of journals should be abbreviated according to the "List of Journals Indexed" in Index Medicus (www.nlm.nih.gov) or MEDLINE (www.nlm.nih.gov). List all authors, but if the number exceeds 3 cite only 3 followed by et al. Examples follow.

Standard journal article


Article not in English

Xu CM. The progression of genetic polymorphism of chemotherapeutics metabolism enzyme. Foreign Medical Science (Genetics Section) 2003;26:156-159 (Chinese).

Organization as an author


No author given


Volume with supplement

Part of a volume

Pagination in Roman numerals

Books

Chapter in a book

Material in press

Electronic material

Tables
Tables must be concise and cited consecutively using Arabic numerals in the text (Table 1, Table 2, etc.). Each table should be typed on a separate sheet. The title of the table should clearly indicate the nature of the contents and sufficient detail should be included in the footnotes to facilitate interpretation without reference to the text. Use horizontal lines only. Reference to the tables should be placed in an appropriate place in the text.

Figures
Figures (photographs, drawings, diagrams and charts) should be clear, easily legible and cited consecutively using Arabic numerals in the text (Fig.1, Fig.2, etc.) Legends for figures should be typed or printed out using double spacing. Briefly explain the symbols, arrows,
numbers, or letters in the illustrations. Identify the method of staining and magnification of the photomicrographs (eg, H&E stain, ×900). Reference to the figures should be placed in an appropriate place in the text.

**Abbreviations**
Avoid unnecessary abbreviations and acronyms, especially in the title. Use uncommon abbreviations and acronyms sparingly, since extensive use renders the text hard to follow. At the first appearance in the abstract and in the text the abbreviation or acronym should be preceded by its full spelling. Use italics when describing a biological species and genus, eg. *Escherchia coli*. If the organism is mentioned again, use a standard abbreviation, eg. *E. coli*. Do not use italics for terms such as in vitro, in vivo, in situ, etc.

**Statistical data**
Present as mean ± SD or mean ± SE.

**Statistical expression**
Express t test as *t* (in italics), F test as *F* (in italics), chi square test as *χ*² (in Greek), related coefficient as *r* (in italics), degrees of freedom as *γ* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Publication Process**

**Submission**
Manuscripts in MS word attachments should be submitted via E-mail to: 2008cocr@gmail.com. In a covering letter, please identify the person responsible for editorial correspondence (address, telephone and fax number, mobile phone and e-mail address).

**Proof of financial support**
For research supported by a foundation, authors should provide a copy of the award document.

**No publication charges**

**Address for Editorial Office correspondence**

Clinical Oncology and Cancer Research
Tianjin Cancer Institute and Hospital,
Bin-Shui Road, Hexi District,
Tianjin 300060, P.R. China
E-mail: 2008cocr@gmail.com
Tel: 86-22-2352 2919
Fax: 86-22-2352 2919